Want to see HK:0460 full AI Analyst Report?

Sihuan Pharmaceutical Holdings Group (0460) Price & Analysis

1 Followers

0460 Stock Chart & Stats

HK$1.32

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$1.32

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.82 - HK$1.92

Previous CloseN/A

Volume8.01M

Average Volume (3M)37.54M

Market Cap

HK$7.74B

Enterprise ValueHK$4.19B

Total Cash (Recent Filing)HK$4.10B

Total Debt (Recent Filing)HK$1.01B

Price to Earnings (P/E)36.6

Beta1.09

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.87%

Share Statistics

EPS (TTM)0.02

Shares Outstanding9,329,999,000

10 Day Avg. Volume24,963,024

30 Day Avg. Volume37,542,935

Financial Highlights & Ratios

PEG Ratio-0.30

Price to Book (P/B)1.72

Price to Sales (P/S)3.85

P/FCF Ratio-46.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$1.75

Price Target Upside32.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.07

Revenue Forecast (FY)HK$3.56B

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryA 21.6% revenue rebound and return to positive net income in 2025 signal restored commercial traction and product demand across hospital channels. Sustained top-line recovery supports cash generation, funds R&D and commercial investment, and improves the probability of durable earnings improvement over coming quarters.

High Gross MarginsConsistently high gross margins (~65–70%) provide structural earnings leverage, giving the company scope to absorb pricing pressure and support SG&A or R&D spending without immediate margin collapse. This margin profile is a durable buffer that can preserve profitability through cyclical revenue swings if operational execution holds.

Low Leverage / Strong Balance SheetDebt-to-equity improving to about 0.16 and a sizable equity base means low financial leverage and a meaningful cushion against shocks. This enhances flexibility for capex, R&D or selective M&A, reduces refinancing risk and supports resilience across business cycles over the medium term.

Bears Say

Weak Cash GenerationOperating cash flow dipping negative while free cash flow was deeply negative in 2025—despite reported net income—signals weak cash conversion and raises earnings-quality concerns. Persistent FCF inconsistency limits financial flexibility, could constrain reinvestment or dividends, and increases reliance on external funding if not corrected.

Earnings VolatilityMulti-year profit swings (large loss in 2022, negative margins in 2024 and recovery in 2025) indicate execution or cyclical risk. Low ROE (~3% in 2025) shows limited shareholder returns. This volatility undermines predictability for planning, capital allocation and long-term investor confidence absent sustained improvement.

Regulatory & Reimbursement ExposureRevenue is concentrated in hospital-channel drug sales and explicitly depends on pricing, tendering and reimbursement policies in China. Persistent regulatory and reimbursement risk can materially affect volumes, pricing and margins over time, making revenue and profit durability sensitive to policy shifts beyond the company’s control.

Sihuan Pharmaceutical Holdings Group News

Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of Anaprazole

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group announced that China’s...

1d ago

Sihuan Pharmaceutical Shareholders Approve All AGM Resolutions and Capital Mandates

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has provided an announcement. Sihuan Pharmaceutical Holdings Group reported that all...

5d ago

Sihuan’s Xuanzhu Biopharm Launches Phase III Trial for Anaprazole in H. pylori Therapy

The latest update is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical’s subsidiary Xuanzhu Biopharm...

10d ago

Sihuan Pharmaceutical Buys Shares for Award Scheme as Medical Aesthetics Surges

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has executed a...

23d ago

Sihuan Pharmaceutical Buys Shares for Award Scheme as Medical Aesthetics Drives Profitable Growth

An announcement from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical’s trustee has purchased...

28d ago

Sihuan Pharmaceutical Sets 2026 AGM to Approve FY2025 Results, Dividend and Share Issuance Mandate

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical Holdings Group has called its...

29d ago

Sihuan Pharmaceutical Forms AI-Driven Medical Aesthetics JV with dProtein

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an update. Sihuan Pharmaceutical has signed a cooperation agreement...

1M ago

Sihuan Pharma Buys Shares for Award Scheme as Medical Aesthetics Drives Profit Turnaround

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an update. Sihuan Pharmaceutical Holdings Group has instructed the...

1M ago

Sihuan Pharmaceutical Launches Share Buyback as Medical Aesthetics Surge Drives Return to Profit

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has announced a...

1M ago

Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an update. Sihuan Pharmaceutical Holdings Group has strengthened its...

2M ago

0460 FAQ

What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?

Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was HK$0.82 and its highest was HK$1.92 in the past 12 months.

What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?

Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is HK$7.74B.

When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?

Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 62 days.

How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?

Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.009 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.009.

Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?

According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?

Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of HK$0.011 which represents an annual dividend yield of 0.87%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here

What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?

Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?

Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.

What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?

Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of HK$0.009 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.512%.

Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?

Currently, no hedge funds are holding shares in HK:0460

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China and the United States. It operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions. It also provides drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. In addition, the company involved in the provision of research and development, and industrialization of innovative medicine; construction for medical project; provision of general hospital services and hospital management services; and property investment business. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.

Sihuan Pharmaceutical Holdings Group (0460) Earnings & Revenues

Historic Earnings Reports

0460 Stock 12 Month Forecast

Average Price Target

HK$1.75

▲(32.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"HK$0","1":"HK$1","2":"HK$2","3":"HK$3","-1":"-HK$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$1.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.958,1.0381538461538462,1.1183076923076922,1.1984615384615385,1.2786153846153847,1.3587692307692307,1.438923076923077,1.519076923076923,1.5992307692307692,1.6793846153846155,1.7595384615384615,1.8396923076923077,1.9198461538461538,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.958,1.0189230769230768,1.079846153846154,1.1407692307692308,1.2016923076923076,1.2626153846153847,1.3235384615384616,1.3844615384615384,1.4453846153846155,1.5063076923076923,1.5672307692307692,1.6281538461538463,1.6890769230769231,{"y":1.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.958,0.9996923076923077,1.0413846153846154,1.083076923076923,1.1247692307692307,1.1664615384615384,1.2081538461538461,1.2498461538461538,1.2915384615384615,1.3332307692307692,1.374923076923077,1.4166153846153846,1.4583076923076923,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.922,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.088,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.275,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.491,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.461,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.333,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.214,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.531,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.451,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.432,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.254,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.958,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >